Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases

被引：0

作者：

Ichinose, Kunihiro ^{[1
]}

Origuchi, Tomoki ^{[2
]}

Kawashiri, Shin-ya ^{[1
]}

Iwamoto, Naoki ^{[1
]}

Fujikawa, Keita ^{[1
]}

Aramaki, Toshiyuki ^{[1
]}

Kamachi, Makoto ^{[1
]}

Arima, Kazuhiko ^{[1
]}

Tamai, Mami ^{[1
]}

Nakamura, Hideki ^{[1
]}

Ida, Hiroaki ^{[1
]}

Kawakami, Atsushi ^{[1
]}

Eguchi, Katsumi ^{[1
]}

机构：

[1] Nagasaki Univ, Dept Rheumatol, Unit Translat Med, Grad Sch Biomed Sci, Nagasaki 8528501, Japan

[2] Nagasaki Univ, Dept Phys Therapy, Unit Rehabil, Grad Sch Biomed Sci, Nagasaki 8528501, Japan

来源：

RHEUMATOLOGY INTERNATIONAL | 2012年 / 32卷 / 02期

关键词：

Rheumatoid arthritis (RA); Adalimumab; Long-term; DAS28-CRP; ANTITUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODY; METHOTREXATE; RISK; TUBERCULOSIS; EFFICACY; THERAPY; DISEASE; SAFETY;

D O I：

10.1007/s00296-010-1770-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We present six cases of patients with Japanese rheumatoid arthritis (RA) treated with a tumor necrosis factor (TNF)-alpha blocking agent, adalimumab as monotherapy for 220 weeks. All six patients were women, and the median age was 54.0 +/- A 7.07 years old. The median duration of the disease was 7.43 +/- A 11.1 years, and the median disease activity score (DAS28-CRP) was 5.35 +/- A 0.69. Three of six patients were able to continue to receive this treatment for 220 weeks successfully, and the DAS28-CRP decreased to 1.89 +/- A 0.75. Two patients withdrew because of lack of efficacy, and one patient withdrew because of adverse events (non-Hodgkin lymphoma). Adalimumab resulted in a sustained clinical response in RA patients during 220-week follow-up.

引用

页码：483 / 487

页数：5

共 50 条

[1] Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases
Kunihiro Ichinose
Tomoki Origuchi
Shin-ya Kawashiri
Naoki Iwamoto
Keita Fujikawa
Toshiyuki Aramaki
Makoto Kamachi
Kazuhiko Arima
Mami Tamai
Hideki Nakamura
Hiroaki Ida
Atsushi Kawakami
Katsumi Eguchi
Rheumatology International, 2012, 32 : 483 - 487
[2] JUVENILE RHEUMATOID ARTHRITIS - A LONG-TERM FOLLOW-UP
BARKIN, RE
ANNALS OF THE RHEUMATIC DISEASES, 1952, 11 (04) : 316 - 317
[3] Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: A prospective long-term follow-up
Atzeni, Fabiola
Doria, Andrea
Ghirardello, Anna
Villalta, Danilo
Zampieri, Sandra
Carrabba, Mario
Sarzi-Puttini, Piercarlo
AUTOIMMUNITY, 2008, 41 (01) : 87 - 91
[4] COMBINATION VS MONOTHERAPY FOR POOR PROGNOSIS RHEUMATOID ARTHRITIS: A LONG-TERM FOLLOW-UP STUDY
Bejarano, V.
Philip, C.
Michael, G.
Heather, K.
Paul, E.
RHEUMATOLOGY, 2004, 43 : 45 - 45
[5] Intraventricular craniopharyngioma: a long-term follow-up of six cases
Davies, MJ
King, TT
Metcalfe, KA
Monson, JP
BRITISH JOURNAL OF NEUROSURGERY, 1997, 11 (06) : 533 - 541
[6] Combination vs monotherapy for poor prognosis rheumatoid arthritis: A long-term follow-up study.
Bejarano, V
Conaghan, P
Green, M
King, H
Emery, P
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S125 - S125
[7] A long-term follow-up of zonisamide monotherapy
Fukushima, Katsuyuki
Seino, Masakazu
EPILEPSIA, 2006, 47 (11) : 1860 - 1864
[8] Long-term follow-up of the cervical spine with conventional radiographs in patients with rheumatoid arthritis
Blom, M.
Creemers, M. C. W.
Kievit, W.
Lemmens, J. A. M.
van Riel, P. L. C. M.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (04) : 281 - 288
[9] Extended follow-up of the long-term safety of rituximab in rheumatoid arthritis
Emery, Paul
van Vollenhoven, Ronald F.
Binghamlll, Clifton O.
Keystone, Edward C.
Greenwald, Maria
Moreland, Larry W.
Sweetser, Marianne
Rowe, Karen
Wagner, Bridget
Magrini, Fabio
RHEUMATOLOGY, 2008, 47 : II16 - II16
[10] KNEE SYNOVECTOMY IN RHEUMATOID-ARTHRITIS - LONG-TERM FOLLOW-UP
LAURIN, CA
DESMARCH.J
GARIEPY, R
DAZIANO, L
DEROME, A
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1973, A 55 (06): : 1304 - 1304

← 1 2 3 4 5 →